| Dr David Tkeshelashvili, MD | |
|
60 Westwood Ave, Suite320, Waterbury, CT 06708-2460 | |
| (203) 756-8995 | |
| (203) 756-4041 |
| Full Name | Dr David Tkeshelashvili |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 32 Years |
| Location | 60 Westwood Ave, Waterbury, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306878731 | NPI | - | NPPES |
| 1361138 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 036113 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hartford Hospital | Hartford, CT | Hospital |
| The Hospital Of Central Connecticut | New britain, CT | Hospital |
| Midstate Medical Center | Meriden, CT | Hospital |
| William W Backus Hospital | Norwich, CT | Hospital |
| St. Vincent's Medical Center | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Entity Name | The Charlotte Hungerford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629075734 PECOS PAC ID: 4486557501 Enrollment ID: O20040128000183 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Entity Name | Waterbury Neurology, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255378501 PECOS PAC ID: 0042247082 Enrollment ID: O20050721000590 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Entity Name | St. Vincent's Multispecialty Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043544489 PECOS PAC ID: 6204977218 Enrollment ID: O20100112000538 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Entity Name | Prospect Waterbury Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477902641 PECOS PAC ID: 4688967581 Enrollment ID: O20161004000255 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Tkeshelashvili, MD 60 Westwood Ave, Suite320, Waterbury, CT 06708-2460 Ph: (203) 756-8995 | Dr David Tkeshelashvili, MD 60 Westwood Ave, Suite320, Waterbury, CT 06708-2460 Ph: (203) 756-8995 |
News Archive
One small molecule that helps regulate gene expression plays a big role in keeping us safe from the machinations of cancer, scientists report.
Although the remarkable benefits of combined training have been clarified by numerous investigations, fitness enthusiasts struggle with the same question: Does the order of cardio- and resistance training influence the effectiveness of a training program?
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).
Labopharm Inc. today commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products L.P. against Par Pharmaceutical Companies, Inc. relating to Ultram(R) ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are owned by Purdue and are licensed to Ortho-McNeil, Inc., the marketer of Ultram(R) ER.
› Verified 2 days ago
Eleanor Elizabeth Stutz, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 95 Thomaston Ave, Dmhas - Wcmhn, Waterbury, CT 06702 Phone: 203-805-5300 Fax: 203-805-5310 | |
Dr. Steven Eric Schneider, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 64 Robbins St, Waterbury, CT 06708 Phone: 203-573-7141 Fax: 203-573-6161 | |
Judith Karen Carlson, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 55 West Main Street Suite 410, Western Connecticut Mental Health Network, Waterbury, CT 06702 Phone: 203-805-6408 Fax: 203-805-6432 | |
Dr. Jeffrey Howard Boyd, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 969 W Main St, Waterbury, CT 06708 Phone: 203-573-8555 Fax: 203-597-9565 | |
Rosina I Bandanza, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 95 Thomaston Ave, Western Connecticut Menatl Health Network, Waterbury, CT 06702 Phone: 203-805-5300 Fax: 203-805-5310 | |
Alok Bhargava, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 134 Grandview Ave, Suite 208, Waterbury, CT 06708 Phone: 203-755-3279 Fax: 203-755-3057 | |
Sabooh Mubbashar, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 64 Robbins St, Crisis Intervention Center, Waterbury, CT 06708 Phone: 203-573-6500 Fax: 203-573-7007 |